x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DPP-001178
| Product Overview | |
|---|---|
| Species | Human, Rat, Mouse, Pig, Chicken, Frog |
| Format | Lyophilized |
| Purity | ≥ 95% by Densitometry |
| Target Information | |
|---|---|
| UniProt No. | P61278; P60042; P60041; P01168; O46688; F1MV99 |
| Molecular Formula | C76H104N18O19S2 |
| Molecular Weight | 1638 |
| Function | Somatostatin [SST, GHIH (growth hormone-inhibiting hormone) or SRIF (somatotropin release-inhibiting factor)] is a cyclic peptide hormone existing as two isoforms and produced in the pancreas islet, GI tract and the central nervous system. Tetradecapeptide Somatostatin-14 (SRIF-14, the originally identified somatostatin) and the 28-amino acid Somatostatin-28 (SRIF-28) have similar biological activities but differ in their potency. Somatostatins regulate the endocrine system: they inhibit the release of growth hormone in contrast to Growth Hormone Factor (GRF), which stimulates the release of growth hormone. They also inhibit the release of prolactin and thyrotropin, peptide hormones from the pituitary gland and glucagon and insulin from the pancreas. They control the secretion of gut hormones and function as neurotransmitters. |
| Sequence | AGCKNFFWKTFTSC (Disulfide bridge: 3-14) |
| Sequence | H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH (Disulfide bridge: 3-14) |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped on dry ice. |
| Storage | Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
